These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6184099)

  • 21. Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy.
    Nomura Y
    Int J Oncol; 1998 Apr; 12(4):817-24. PubMed ID: 9499441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of breast cancer.
    Cohen IA; Keller JH; Abate MA
    Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
    Nicolini A; Carpi A
    Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined chemo-hormonal therapy in breast cancer: a hypothesis.
    Osborne CK
    Breast Cancer Res Treat; 1981; 1(2):121-3. PubMed ID: 7348568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer.
    Labrie F; Champagne P; Labrie C; Roy J; Laverdière J; Provencher L; Potvin M; Drolet Y; Pollak M; Panasci L; L'Espérance B; Dufresne J; Latreille J; Robert J; Samson B; Jolivet J; Yelle L; Cusan L; Diamond P; Candas B
    J Clin Oncol; 2004 Mar; 22(5):864-71. PubMed ID: 14990642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Endocrine therapy of recurrent breast cancer].
    Nomura Y; Tashiro H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):421-7. PubMed ID: 3890756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial.
    Hubay CA; Pearson OH; Marshall JS; Rhodes RS; DeBanne SM; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL
    Cancer; 1980 Dec; 46(12 Suppl):2805-8. PubMed ID: 7004624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors.
    Moseley HS; Peetz ME; Keenan EJ; Awrich AE; Fletcher WS
    Am J Surg; 1980 Jul; 140(1):164-72. PubMed ID: 7396080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
    Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
    J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy.
    Manni A; Arafah B; Pearson OH
    Cancer; 1980 Dec; 46(12 Suppl):2838-41. PubMed ID: 7448730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.
    J Natl Cancer Inst; 1996 Dec; 88(24):1834-9. PubMed ID: 8961973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen therapy of metastatic breast cancer.
    Manni A
    J Lab Clin Med; 1987 Mar; 109(3):290-9. PubMed ID: 2950193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters.
    Morgan LR; Schein PS; Woolley PV; Hoth D; Macdonald J; Lippman M; Posey LE; Beazley RW
    Cancer Treat Rep; 1976 Oct; 60(10):1437-43. PubMed ID: 191185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
    Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
    Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.